Latest Anastrozole Stories

New research published in BioMed Central's open access journal BMC Medicine reassessing clinical data from trials, which investigate ways of treating side effects of therapy for prostate cancer, finds that tamoxifen, an anti-estrogen used to treat breast cancer, is also able to suppress gynecomastia and breast pain in men. Prostate cancer is one of the most common cancers in men and early treatment is usually very successful. Androgen-suppression therapy is often used to slow down...

New treatment option extends median survival time by more than 6 months Postmenopausal women with the most common type of metastatic breast cancer now have a new treatment option that lengthens their lives, according a study led by UC Irvine oncologist Dr. Rita Mehta and conducted by the Southwest Oncology Group. The findings appear in the Aug. 2 issue of the New England Journal of Medicine. A combination of the two anti-estrogen drugs anastrozole and fulvestrant extended the median...

Study published in New England Journal of Medicine A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer. The study found that combing two drugs that normally are each given as single agents significantly extended the lives of women with metastatic breast cancer. Kathy Albain, MD, a breast cancer specialist at Loyola University Medical Center, is among the main authors of the study....

WALTHAM, Mass., May 29, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company, announced today that updated results from ENCORE 301, a randomized, placebo-controlled phase 2 study of exemestane with and without entinostat in estrogen receptor positive metastatic breast cancer demonstrated improvement in overall survival for patients treated with exemestane plus entinostat. At median follow up of 25 months, treatment with the combination resulted in an...

IRVING, Texas, April 12, 2012 /PRNewswire/ -- For years menopausal women heard that estrogen increases breast cancer risk. A March 2012 study in Lancet Oncology analyzing data from the Women's Health Initiative (WHI) reported that menopausal women taking estrogen only have a lower risk of breast cancer while women who take a combination pill (Prempro) of estrogen-progestin have an increased risk. Recognized endocrinologist Dr. Marina Johnson shares her thoughts on the data: "At first...

Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone. Professor Michael Gnant told the eighth European Breast Cancer Conference (EBCC-8) today (Friday) that the latest results from the BOLERO-2 trial would change clinical practice. "These results...

Treatment with aromatase inhibitors enables some women to have lumpectomy Preoperative treatment with aromatase inhibitors increases the likelihood that postmenopausal women with estrogen receptor-positive breast cancer will be able to have breast-conserving surgery rather than a mastectomy, according to the results of a national clinical trial presented today at the Society of Surgical Oncology annual meeting in Orlando, Fla. "We found that half of the postmenopausal women in the study...

Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness of CYP2D6 testing for deciding whether or not a patient should receive adjuvant tamoxifen for treatment of early-stage breast cancer. Both studies found that CYP2D6 genotypes that were indicative of reduced activity of enzymes that metabolize tamoxifen did not predict...

(Ivanhoe News Wire) -- A combination of drugs that target estrogen production significantly reduced the number of tobacco carcinogen-induced lung tumors in mice, according to results from a preclinical study. "Antiestrogens have been shown to prevent breast cancer in some women," Jill M. Siegfried, Ph.D., professor in the department of pharmacology and chemical biology at University of Pittsburgh Cancer Institute, was quoted as saying. "If antiestrogens can prevent lung cancer as well,...

A combination of drugs that target estrogen production significantly reduced the number of tobacco carcinogen-induced lung tumors in mice, according to results from a preclinical study. "Antiestrogens have been shown to prevent breast cancer in some women," said Jill M. Siegfried, Ph.D., professor in the department of pharmacology and chemical biology at University of Pittsburgh Cancer Institute. "If antiestrogens can prevent lung cancer as well, this would be a major advance, because...